Page last updated: 2024-12-08
bakkenolide a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
bakkenolide A: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 442173 |
| CHEBI ID | 2984 |
| SCHEMBL ID | 20225099 |
| MeSH ID | M0066155 |
Synonyms (31)
| Synonym |
|---|
| fukinanolide |
| nsc-292655 |
| fukinanolid |
| bakkenolid a |
| C09350 |
| 19906-72-0 |
| bakkenolide a |
| (2r,3ar,7s,7ar)-7,7a-dimethyl-4'-methylidenespiro[3,3a,4,5,6,7-hexahydro-1h-indene-2,3'-oxolane]-2'-one |
| spiro(furan-3(2h),2'-indan)-2-one, 3'a,4,4',5,5',6',7',7'abeta-octahydro-3'abeta,4'beta-dimethyl-4-methylene-, (2'r)- |
| spiro(furan-3(2h),2'-(2h)inden)-2-one, decahydro-3'a,4'-dimethyl-4-methylene-, (2'r-(2'alpha,3'aalpha,4'alpha,7'aalpha))- |
| nsc 292655 |
| (+)-bakkenolide a |
| t86zpp5fmq , |
| unii-t86zpp5fmq |
| S9554 |
| bakkenolide a, (+)- |
| spiro(furan-3(2h),2'-(2h)inden)-2-one, decahydro-3'a,4'-dimethyl-4-methylene-, (2'r,3'ar,4's,7'ar)- |
| spiro(furan-3(2h),2'-(2h)inden)-2-one, decahydro-3'a,4'-dimethyl-4-methylene-, (2'r-(2'.alpha.,3'a.alpha.,4'.alpha.,7'a.alpha.))- |
| spiro(furan-3(2h),2'-indan)-2-one, 3'a,4,4',5,5',6',7',7'a.beta.-octahydro-3'a.beta.,4'.beta.-dimethyl-4-methylene-, (2'r)- |
| CHEBI:2984 |
| ( )-bakkenolide a |
| DTXSID20173684 , |
| SCHEMBL20225099 |
| HY-N6017 |
| FS-9836 |
| bakkenolide |
| mfcd10566620 |
| Q27105910 |
| CS-0032181 |
| AKOS040750440 |
| dtxcid7096175 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " Based on the results, the oral bioavailability of BA in rats at 20 mg/kg is 15." | ( Determination of bakkenolide A in rat plasma using liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. Bao, Y; Chen, F; Chen, X; Dai, D; Li, J; Liu, S; Pei, L; Zheng, J, 2012) | 0.72 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| sesquiterpenoid | Any terpenoid derived from a sesquiterpene. The term includes compounds in which the C15 skeleton of the parent sesquiterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 20.35
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.35) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||